As India presented the Union Budget 2026, market participants approached the policy event with a measured mix of caution and ...
The company reported exceptional items amounting to ₹21.2 crore during the quarter, linked to the implementation of the new ...
The policy move is likely to reduce compliance requirements and lower transaction costs associated with overseas investments ...
As a result of these cuts in spending, the government will still maintain the fiscal deficit at 4.4% of GDP for FY26 and the revenue deficit at 1.5% of GDP. Let us now turn to the big highlights of ...
Revenue for the quarter rose 2.8% to ₹1,004 crore, reflecting steady demand across core brands amid a competitive operating ...
Consolidated net debt stood at ₹15,443 crore at the end of the December quarter, higher than ₹14,156 crore reported as of ...
The India formulations business continued to perform well, with revenue increasing 22% year on year to ₹1,298.6 crore ...
A very high ratio of fiscal deficit to GDP has several negative implications. For starters, it tends to weaken the rupee and ...
While large scale changes in tax rates are unlikely, the markets will look at some smart tweaking of tax rates ...
Union Finance Minister Nirmala Sitharaman announced a major new initiative in the Union Budget 2026, with the central government planning to launch the Bio Pharma Shakti scheme with an outlay of ...
Indian investors not only want a better investing environment, but also more investment options to choose from ...
Revenue from operations rose sharply by 15 percent year on year to ₹1,828 crore, up from ₹1,588 crore in the year ago period ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results